The Efficacy Of Mapping For Cognitive Prostate Biopsy (MAPROSTATE)
Prostate Cancer, Prostate Adenocarcinoma, Prostatic Neoplasms
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring Prostate, Cancer, Mapping, Genitourinary Radiology, Transrectal, Biopsy, Rectal examination, Method, Efficacy, Prostate mapping, Cognitive, prospective, Randomized
Eligibility Criteria
Inclusion Criteria: Patients with elevated serum Prostate Specific Antigen (PSA) Indicated prostate biopsy by MR imaging and underwent Multiparametric Prostate Magnetic Resonance (MPMR) imaging before the procedure Exclusion Criteria: Patients with suspicious Rectal Examination findings Patients who cannot enter Multiparametric Prostate Magnetic Resonance (MPMR) imaging for various reasons (such as Multiparametric Prostate Magnetic Resonance (MPMR) imaging incompatible pacemaker, Chronic Kidney Disease) Patients with diagnosed prostate cancer and active surveillance Patients without indication for prostate biopsy Patients with very high serum Prostate Specific Antigen (PSA) levels (>15) Patients who are planned to start treatment by diagnosing with standard 12 core biopsy without losing time with imaging method Patients who do not want to participate in the study.
Sites / Locations
- Marmara University, School of Medicine, Department of UrologyRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Sham Comparator
Prostate Mapping Used
Prostate Mapping not Used
Those patients' Multiparametric Prostate Magnetic Resonance (MPMR) imaging's have been assessed by a genitourinary radiologist to guide the surgeon who performs cognitive prostate biopsy
Those patients' Multiparametric Prostate Magnetic Resonance (MPMR) imaging's have not been assessed by a genitourinary radiologist to guide the surgeon who performs cognitive prostate biopsy. Surgeon assesses the Multiparametric Prostate Magnetic Resonance (MPMR) imaging's by him/herself